On Thursday morning 08/01/2024 the Merck Co. share started trading at the price of $113.25.
Compared to the closing price on Wednesday 07/31/2024 on BTT of $113.12, this is a gain of 0.11%.
There are 2.53 B shares outstanding in Merck Co., which values the company at $291.15 B.
Is Merck stock a Buy, Sell or Hold?
Merck stock has received a consensus rating of buy. The average rating score is A1 and is based on 56 buy ratings, 12 hold ratings, and 1 sell ratings.What was the 52-week low for Merck stock?
The low in the last 52 weeks of Merck stock was 98.00. According to the current price, Merck is 115.73% away from the 52-week low.What was the 52-week high for Merck stock?
The high in the last 52 weeks of Merck stock was 134.61. According to the current price, Merck is 84.26% away from the 52-week high.What are analysts forecasts for Merck stock?
The 69 analysts offering price forecasts for Merck have a median target of 125.16, with a high estimate of 155.00 and a low estimate of 91.00. The median estimate represents a 90.62 difference from the last price of 113.42.Merck Stock Snapshot
113.08
Bid
50.00
Bid Size
113.12
Ask
150.00
Ask Size
8/1/2024
Date
2:00 PM
Zeit
560,318.00
Volume
113.12
Prev. Close
113.25
Öffnen Sie
291.88 B
Market Cap in USD
2.53 B
Number of Shares
111.41
Day Low
113.82
Day High
113.10
98.00
52 Week Low
134.61
52 Week High
113.10
2.96
Dividend in USD
2.72
Dividend Yield
760.78
P/E Ratio
99.85
Free Float in %
0.14
EPS in USD
14.84
Book Value per Share in USD
5.11
Cash Flow per Share in USD
Merck News More News
Historical Prices for Merck
Date | Öffnen Sie | Schließen Sie | Daily High | Daily Low |
---|
Price change over selected period:
0%
0
Merck Analyst Data
Total Analysts: 69
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 91.00
Median: 125.16
Highest: 155.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Merck Analyst Opinions
- Alle
- Buy
- Hold
- Sell
Date | Analyst | Rating | Price | |||
---|---|---|---|---|---|---|
07/11/24 | Morgan Stanley | Maintained Hold | $134 | |||
06/18/24 | Cantor Fitzgerald | Maintained Buy | $155 | |||
06/04/24 | Cantor Fitzgerald | Maintained Buy | $155 | |||
04/18/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
04/08/24 | Berenberg | Maintained Buy | $143 | |||
04/05/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
04/01/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
03/27/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
03/27/24 | Wells Fargo & Co | Maintained Hold | $135 | |||
03/11/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
02/29/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
02/14/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
02/05/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
02/02/24 | UBS | Maintained Buy | $148 | |||
02/02/24 | Wells Fargo & Co | Maintained Hold | $130 | |||
02/02/24 | Barclays Capital | Maintained Buy | $145 | |||
01/23/24 | Barclays Capital | Maintained Buy | $135 | |||
01/09/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
11/29/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
11/20/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
11/15/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
11/09/23 | Deutsche Bank | Maintained Buy | $115 | |||
10/27/23 | Morgan Stanley | Maintained Hold | $118 | |||
10/27/23 | BMO Capital Markets | Upgraded to Buy | $132 | |||
10/23/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
10/11/23 | Morgan Stanley | Maintained Hold | $115 | |||
10/02/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
09/05/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
08/22/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
08/02/23 | Morgan Stanley | Maintained Hold | $116 | |||
07/14/23 | HSBC | Maintained Sell | $123 | |||
07/11/23 | Morgan Stanley | Maintained Hold | $109 | |||
05/30/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
05/01/23 | Atlantic Equities | Maintained Buy | $129 | |||
05/01/23 | Barclays Capital | Maintained Buy | $130 | |||
04/13/23 | Citigroup Corp. | Upgraded to Buy | $130 | |||
04/11/23 | Guggenheim | Maintained Buy | $124 | |||
04/10/23 | Mizuho | Maintained Buy | $130 | |||
03/17/23 | Mizuho | Maintained Buy | $130 | |||
03/13/23 | Wells Fargo & Co | Downgraded to Hold | $115 | |||
03/10/23 | Berenberg | Maintained Buy | $130 | |||
03/07/23 | Credit Suisse | Maintained Buy | $126 | |||
03/07/23 | Atlantic Equities | Maintained Buy | $127 | |||
03/06/23 | Jefferies & Company Inc. | Maintained Buy | $125 | |||
02/23/23 | J.P. Morgan | Maintained Buy | $125 | |||
02/22/23 | Wolfe Research | Upgraded to Buy | $127 | |||
02/13/23 | Credit Suisse | Maintained Buy | $125 | |||
02/03/23 | Wells Fargo & Co | Maintained Buy | $120 | |||
02/03/23 | Morgan Stanley | Maintained Hold | $99 | |||
02/03/23 | SVB Leerink | Maintained Buy | $122 |
Merck Estimates* in USD
2024 | 2025 | 2026 | 2027 | 2028 | |
---|---|---|---|---|---|
Revenue | 64,189 | 68,740 | 72,785 | 75,693 | 77,362 |
Dividend | 3.14 | 3.35 | 3.56 | 3.60 | 3.70 |
Dividend Yield (in %) | 2.78 % | 2.96 % | 3.15 % | 3.19 % | 3.27 % |
EPS | 8.04 | 9.80 | 10.69 | 11.43 | 11.57 |
P/E Ratio | 14.06 | 11.53 | 10.57 | 9.89 | 9.77 |
EBIT | 25,237 | 29,612 | 31,951 | 33,937 | 33,916 |
EBITDA | 28,286 | 32,422 | 34,604 | 36,778 | 37,969 |
Net Profit | 20,885 | 24,803 | 26,894 | 28,909 | 29,136 |
Net Profit Adjusted | 20,885 | 24,860 | 26,993 | 28,909 | 29,136 |
Pre-Tax Profit | 24,795 | 29,268 | 31,986 | 34,105 | 34,119 |
Net Profit (Adjusted) | 23,720 | 26,556 | 29,827 | 31,380 | 32,512 |
EPS (Non-GAAP) ex. SOE | 8.04 | 9.80 | 10.69 | 11.43 | 11.57 |
EPS (GAAP) | 7.69 | 9.14 | 9.97 | 10.39 | 10.83 |
Gross Income | 51,450 | 54,877 | 57,684 | 60,557 | 62,170 |
Cash Flow from Investing | -8,705 | -9,873 | -9,961 | -9,620 | -10,056 |
Cash Flow from Operations | 23,862 | 26,846 | 29,086 | 30,895 | 29,651 |
Cash Flow from Financing | -8,705 | -9,873 | -9,961 | -9,620 | -10,056 |
Cash Flow per Share | 8.99 | 10.56 | 11.43 | 11.89 | 13.25 |
Free Cash Flow | 18,923 | 22,530 | 25,119 | 25,415 | 26,599 |
Free Cash Flow per Share | 4.56 | 4.63 | 5.71 | - | - |
Book Value per Share | 19.40 | 24.55 | 30.41 | 34.66 | 40.40 |
Net Debt | 19,870 | 6,250 | -4,611 | -23,497 | -39,389 |
Research & Development Exp. | 15,403 | 14,674 | 15,192 | 15,725 | 16,016 |
Capital Expenditure | 3,586 | 3,653 | 3,508 | 2,735 | 2,604 |
Selling, General & Admin. Exp. | 10,908 | 11,360 | 11,808 | 12,008 | 12,182 |
Shareholder’s Equity | 49,421 | 64,928 | 82,617 | 102,036 | 122,664 |
Total Assets | 117,246 | 131,837 | 148,589 | 165,683 | 184,920 |
Previous Quarter ending 06/30/24 |
Current Quarter ending 09/30/24 |
Next Quarter ending 12/31/24 |
Current Year ending 12/31/24 |
Next Year ending 12/31/25 |
|
---|---|---|---|---|---|
Earnings Estimates | |||||
No. of Analysts | - | 14 | 19 | 14 | 22 |
Average Estimate | - | 1.765 USD | 1.961 USD | 8.038 USD | 9.803 USD |
Year Ago | - | 1.870 USD | -0.484 USD | 0.144 USD | - |
Datum veröffentlichen | - | 10/31/2024 | 1/30/2025 | - | - |
Revenue Estimates | |||||
No. of Analysts | - | 17 | 17 | 23 | 23 |
Average Estimate | - | 16,551 USD | 15,778 USD | 64,189 USD | 68,740 USD |
Year Ago | - | 16,007 USD | 14,213 USD | 59,871 USD | - |
Datum veröffentlichen | - | 10/31/2024 | 1/30/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|
Verkauf | 59,871.00 | 58,473.00 | 48,907.00 | 48,013.00 | 46,586.00 | 42,446.00 | 39,981.00 |
Change of sales in % | 2.39 | 19.56 | 1.86 | 3.06 | 9.75 | 6.17 | 1.23 |
Gross profit on sales | 43,894.00 | 41,267.00 | 35,441.00 | 35,421.00 | 32,725.00 | 29,381.00 | 27,402.00 |
Gross profit on sales change in % | 6.37 | 16.44 | 0.06 | 8.24 | 11.38 | 7.22 | 4.86 |
Operating income | 2,982.00 | 19,501.00 | 15,619.00 | 12,566.00 | 13,480.00 | 9,684.00 | 8,001.00 |
Operating income change in % | -84.71 | 24.85 | 24.30 | -6.78 | 39.20 | 21.03 | -23.73 |
Income before tax | 1,889.00 | 16,444.00 | 13,879.00 | 8,791.00 | 11,464.00 | 8,701.00 | 6,521.00 |
Income before tax change in % | -88.51 | 18.48 | 57.88 | -23.32 | 31.75 | 33.43 | 39.97 |
Income after tax | 365.00 | 14,519.00 | 13,049.00 | 7,067.00 | 9,843.00 | 6,220.00 | 2,394.00 |
Income after tax change in % | -97.49 | 11.27 | 84.65 | -28.20 | 58.25 | 159.82 | -38.93 |
Balance Sheet in Mio. USD
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|
Total liabilities | 69,040.00 | 63,102.00 | 67,437.00 | 66,184.00 | 58,396.00 | 55,755.00 | 53,303.00 |
Long-term liabilities per share | 17.12 | 15.31 | 17.24 | 15.36 | 14.25 | 12.94 | 12.86 |
Equity | 37,635.00 | 46,058.00 | 38,257.00 | 25,404.00 | 26,001.00 | 26,882.00 | 34,569.00 |
Equity change in % | -18.29 | 20.45 | 50.82 | -2.28 | -2.97 | -22.24 | -14.35 |
Balance sheet total | 106,675.00 | 109,160.00 | 105,694.00 | 91,588.00 | 84,397.00 | 82,637.00 | 87,872.00 |
Balance sheet total change in % | -2.28 | 3.28 | 15.40 | 8.52 | 2.13 | -5.96 | -7.87 |
Key Data in USD
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|
Sales per share | 23.51 | 23.00 | 19.27 | 18.90 | 18.06 | 15.84 | 14.55 |
P/E ratio (year end quote, basic EPS) | 760.78 | 19.43 | 14.91 | 29.41 | 23.84 | 32.94 | 64.68 |
P/E ratio (year end quote, diluted EPS) | 760.78 | 19.43 | 14.91 | 29.41 | 23.84 | 32.94 | 64.68 |
P/E ratio (year end quote) | 760.78 | 19.43 | 14.91 | 29.41 | 23.84 | 32.94 | 64.68 |
Dividend yield in % | 2.72 | 2.52 | 3.44 | 3.03 | 2.48 | 2.60 | 3.36 |
Equity ratio in % | 35.23 | 42.13 | 36.13 | 27.64 | 30.70 | 32.31 | 39.08 |
Debt ratio in % | 64.72 | 57.81 | 63.80 | 72.26 | 69.19 | 67.47 | 60.66 |
Merck Insider Activity
Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
---|---|---|---|---|---|---|
DeLuca Richard R. | 05/03/2024 | 13,360.00 | 150,359.56 | 127.51 | Sell | No |
Klobuchar Michael A | 05/03/2024 | 437.00 | 23,621.20 | 127.51 | Sell | No |
Smart Dalton | 05/03/2024 | 302.00 | 4,428.29 | 127.51 | Sell | No |
DeLuca Richard R. | 05/03/2024 | 27,126.00 | 163,719.56 | 127.51 | Buy | No |
Klobuchar Michael A | 05/03/2024 | 887.00 | 24,058.20 | 127.51 | Buy | No |
Smart Dalton | 05/03/2024 | 612.00 | 4,730.29 | 127.51 | Buy | No |
Smart Dalton | 05/02/2024 | 255.00 | 3,178.29 | 128.26 | Sell | No |
Smart Dalton | 05/02/2024 | 590.00 | 4,118.29 | 128.26 | Sell | No |
Smart Dalton | 05/02/2024 | 1,530.00 | 4,708.29 | 128.26 | Buy | No |
Smart Dalton | 05/02/2024 | 516.00 | 3,433.29 | 128.26 | Buy | No |
Romanelli Joseph | 05/01/2024 | 1,115.00 | 20,716.33 | 128.80 | Sell | No |
Romanelli Joseph | 05/01/2024 | 2,262.00 | 21,831.33 | 128.80 | Buy | No |
Litchfield Caroline | 02/13/2024 | 38,291.00 | 50,908.19 | 125.50 | Sell | No |
Litchfield Caroline | 02/13/2024 | 38,291.00 | 89,199.19 | 58.08 | Buy | No |
MIZELL STEVEN | 02/01/2024 | 50,694.00 | 23,619.15 | 126.65 | Sell | No |
MIZELL STEVEN | 02/01/2024 | 32,170.00 | 74,313.15 | 73.73 | Buy | No |
MIZELL STEVEN | 02/01/2024 | 824.00 | 42,143.15 | 70.71 | Buy | No |
Chattopadhyay Sanat | 01/21/2024 | 26,716.00 | 26,716.00 | 119.43 | Buy | No |
Oosthuizen Johannes Jacobus | 01/21/2024 | 3,133.00 | 21,349.35 | 119.43 | Buy | No |
Williams David Michael | 01/21/2024 | 10,196.00 | 21,262.67 | 119.43 | Buy | No |
Davis Robert M | 01/21/2024 | 76,510.00 | 348,326.76 | 119.43 | Buy | No |
Litchfield Caroline | 01/21/2024 | 19,208.00 | 50,908.19 | 119.43 | Buy | No |
Zachary Jennifer | 01/21/2024 | 23,298.00 | 59,139.76 | 119.43 | Buy | No |
Klobuchar Michael A | 01/21/2024 | 3,896.00 | 23,098.14 | 119.43 | Buy | No |
DeLuca Richard R. | 01/21/2024 | 23,296.00 | 135,782.98 | 119.43 | Buy | No |
Merck Dividend Calendar
Date | Name | Dividend | *yield | Currency |
---|---|---|---|---|
2023 | Merck Co. | 2.96 | 2.72 | USD |
2022 | Merck Co. | 2.80 | 2.52 | USD |
2021 | Merck Co. | 2.64 | 3.44 | USD |
2020 | Merck Co. | 2.48 | 3.03 | USD |
2019 | Merck Co. | 2.26 | 2.48 | USD |
2018 | Merck Co. | 1.99 | 2.60 | USD |
2017 | Merck Co. | 1.89 | 3.36 | USD |
2016 | Merck Co. | 1.85 | 3.14 | USD |
2015 | Merck Co. | 1.81 | 3.43 | USD |
2014 | Merck Co. | 1.77 | 3.12 | USD |
2013 | Merck Co. | 1.73 | 3.46 | USD |
2012 | Merck Co. | 1.69 | 4.13 | USD |
2011 | Merck Co. | 1.56 | 4.14 | USD |
2010 | Merck Co. | 1.52 | 4.22 | USD |
2009 | Merck Co. | 1.52 | 4.16 | USD |
2008 | Merck Co. | 1.52 | 5.00 | USD |
2007 | Merck Co. | 1.52 | 2.62 | USD |
2006 | Merck Co. | 1.52 | 3.49 | USD |
2005 | Merck Co. | 1.52 | 4.78 | USD |
2004 | Merck Co. | 1.49 | 4.64 | USD |
2003 | Merck Co. | 1.45 | 3.14 | USD |
2002 | Merck Co. | 1.41 | 2.49 | USD |
2001 | Merck Co. | 1.37 | 2.33 | USD |
2000 | Merck Co. | 1.21 | 1.29 | USD |
1999 | Merck Co. | 1.12 | 1.67 | USD |
*Yield of the Respective Date
Merck Co. Calendar
Event | Estimate | Info | Date |
---|---|---|---|
Earnings Report | 1.765 USD | Q3 2024 Earnings Release | 10/31/2024 |
Earnings Report | 1.961 USD | Q4 2024 Earnings Release | 01/30/2025 |
Earnings Report | 2.395 USD | Q1 2025 Earnings Release | 04/24/2025 |
Earnings Report | 2.405 USD | Q2 2025 Earnings Release | 08/05/2025 |
Earnings Report | 2.575 USD | Q3 2025 Earnings Release | 10/23/2025 |
Merck Co. Past Events
Event | Actual EPS | Info | Date |
---|---|---|---|
Press Conference | - | - | 07/30/2024 |
Press Conference | - | - | 08/01/2023 |
Merck Profile
Merck & Co. , Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Moody’s Daily Credit Risk Score
Merck Shareholder
Owner | in % |
---|---|
Freefloat | 99.85 |
The Vanguard Group, Inc. | 9.66 |
Vanguard Group, Inc. (Subfiler) | 9.16 |
State Street Corp. | 4.64 |
Wellington Management Co. LLP (Wellington Breakout) | 3.19 |
Vanguard Total Stock Market ETF | 3.16 |
BlackRock Fund Advisors | 2.83 |
Vanguard 500 Index Fund | 2.57 |
Geode Capital Management LLC | 2.23 |
BlackRock Institutional Trust Co. NA | 2.23 |
Fidelity Management & Research Co. LLC | 1.59 |
Fidelity 500 Index Fund | 1.22 |
Norges Bank (13F) | 1.13 |
Government Pension Fund - Global (The) | 1.10 |
iShares Core S&P 500 ETF | 1.06 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Merck Management
Name | Job |
---|---|
James Matteucci | Associate Director-State Government Affairs |
Robert M. Davis | Chairman, President & Chief Executive Officer |
Caroline A. Litchfield | Chief Financial Officer & Executive Vice President |
Betty D. Larson | Chief Human Resources Officer & Executive VP |
Dave Williams | Chief Information & Digital Officer |
Chirfi Guindo | Chief Marketing Officer-Human Health & SVP |
Michael Klobuchar | Chief Strategy Officer & Executive Vice President |
Sanat Chattopadhyay | EVP & President-Merck Manufacturing Division |
Dean Y. Li | EVP & President-Merck Research Laboratories |
Brooke Hinkson | Executive Director-Global Clinical Data Standards |
Jennifer Zachary | Executive Vice President & General Counsel |
Richard R. DeLuca | Executive Vice President & President-Animal Health |
Kathy J. Warden | Independent Director |
Patricia Fiorello Russo | Independent Director |
Inge G. Thulin | Independent Director |
Douglas M. Baker | Independent Director |
Mary Ellen Coe | Independent Director |
Pamela J. Craig | Independent Director |
Risa J. Lavizzo-Mourey | Independent Director |
Paul B. Rothman | Independent Director |
Christine E. Seidman | Independent Director |
Stephen L. Mayo | Independent Director |
Thomas Henry Glocer | Lead Independent Director |
Sylvia A. Ayler | Legal Director |
Carol Bowden | Med Aff. Dir, Cardiovascular Metabolism, NorCal |
Allan Gabor | President-Asian-Pacific-BioPharma Business |
Joseph Romanelli | President-Human Health International |
Jannie Oosthuizen | President-Merck Human Health |
Andre Musto | SVP & Head-Gbl Cardiometabolic & Endoc Franchise |
Kelly E. W. Grez | Secretary |
Fiona Hamilton Marshall | Senior VP & Global Head-Discovery Sciences |
Eric H. Rubin | Senior VP-Global Clinical Oncology |
Dalton E. Smart | Senior Vice President-Finance & Global Controller |
Denise Williams | Vice President |
Johanna Herrmann | Vice President-Global Communications |
Peter Dannenbaum | Vice President-Investor Relations |